固態腫瘤檢測全球市場報告：趨勢、預測和競爭分析（至 2031 年）

全球固態腫瘤檢測市場前景光明，醫院、製藥和生物技術公司、受託研究機構和學術研究機構都存在機會。預計到 2031 年，全球固態腫瘤檢測市場規模將達到 16,992 億美元，2025 年至 2031 年的複合年成長率為 3.5%。市場的主要驅動力是補充劑和類固醇的使用增加，以及吸煙和飲酒等不健康習慣的增加。

• Lucintel 表示，根據應用情況，由於全球皮膚腫瘤和相關疾病的發生率不斷增加，預計黑色素瘤將在預測期內出現最高成長。
• 根據最終用途，由於腫瘤和慢性病的盛行率上升，預計醫院將呈現最高的成長。
• 根據地區分類，預計北美將在預測期內出現最高成長，這得益於強大的醫療保健基礎設施支持下各種器官特異性癌症病例的增加。

固態腫瘤檢測市場的策略性成長機會

固態腫瘤檢測領域的幾何發展涵蓋了與組成地理系統的基礎區域相關的各種策略排除選項。具體潛在價值的發展將有助於解決改善診斷過程和治療結果的挑戰。

• 引入個人化醫療：個人化醫療可以設計適合每位患者的獨特測試。透過全面研究基因，可以設計出更有效地治療疾病和改善患者健康狀況的新策略。
• 液態切片市場演變：看到非侵入性檢測的趨勢日益成長，公司看到了增強液態切片系統和服務的機會。這種趨勢不僅提高了患者的舒適度，還能更好地衡量治療效果。
• 將AI技術應用於診斷：AI在固態腫瘤檢測中的應用為智慧診斷解決方案的開發開闢了新的途徑。這些可以系統地篩選大量資訊，以提高測試準確性，提高工作流程效率並縮短診斷時間。
• 早期檢測的需求日益增加：隨著我們對癌症及其早期症狀的了解不斷加深，對更好的篩檢工具的需求也日益增加。因此，致力於向市場提供更好的早期檢測測試的主要企業將能夠更好地從行業日益成長的需求中獲益，進而從不斷擴大的客戶群中奪取更大的市場佔有率。
• 瞄準已開發市場－發展海外業務：新興市場，尤其是亞洲和非洲的市場，可望成為固態腫瘤檢測業務的絕佳途徑。能夠策略性地進入這些地區的公司會發現，越來越多的患者正在尋求更好的診斷方法。

這些前瞻性的成長策略正在重新定義固態腫瘤檢測市場，並專注於精準醫療、技術和新型診斷解決方案。抓住這些機會的供應商可能會獲得更多的市場佔有率並提高為患者提供的護理品質。

固態腫瘤檢測市場促進因素與挑戰

與目前的固態腫瘤檢測市場類似，未來的固態腫瘤檢測市場也受到多種技術、經濟和監管因素的困擾，這些因素既是促進因素，也是限制因素。隨著環境的不斷變化，相關人員了解這些動態非常重要。

固態腫瘤檢測市場受以下因素驅動：

1. 技術進步：液態切片和基因組分析等檢測方法的創新正在推動市場發展。最重要的是，這些創新將提高精準度，針對特定的治療方法，並改善患者獲得多樣化治療方法的機會。

2. 癌症發生率不斷上升：全球癌症發生率的不斷上升要求更好的檢測技術。隨著越來越多的人尋求早期診斷服務和適當的治療方法，固態腫瘤檢測市場持續成長。

3. 轉向個人化治療：人們對精準醫療的興趣日益濃厚，推動著固態腫瘤檢測的模式轉移。越來越多的患者和醫療保健提供者尋求能夠揭示特定突變的測試，以便採用更有效的標靶治療進行治療。

4. 政府政策激勵：監管機構鼓勵創新測試理念並縮短新設備的上市時間。這樣的氛圍將鼓勵研發活動，並最終增加最新和先進診斷設備的供應。

5. 醫療保健資金的成長：固態腫瘤檢測市場的成長受到公共和私人機構對醫療保健基礎設施和生物技術的投資所推動。資金籌措的增加將鼓勵創造和使用複雜的診斷方法。

固態腫瘤檢測市場面臨的挑戰包括：

1. 監管障礙：雖然有時可以獲得監管部門的核准，但獲得新技術的核准可能具有挑戰性。創新公司將難以將尖端解決方案推向市場，從而損害其競爭力。

2. 市場分散：次發性惡性腫瘤檢測市場整合度較低，許多相關人員提供不同的服務。這種分散性導致醫療保健提供者和患者感到困惑，從而導致錯誤的檢測選擇。

支持固態腫瘤檢測市場發展的因素與阻礙其擴張的因素之間的平衡非常明確。為了改善患者照護並促進癌症診斷的有效和進步發展，必須利用現有的技術發展並應對挑戰。

目錄

第1章執行摘要

2. 全球固態腫瘤檢測市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業驅動力與挑戰

第3章市場趨勢與預測分析（2019-2031）

• 宏觀經濟趨勢（2019-2024）及預測（2025-2031）
• 全球固態腫瘤檢測市場趨勢（2019-2024）及預測（2025-2031）
• 全球固態腫瘤檢測市場（按類型）
  • 基因檢測
  • 常規測試
• 全球固態腫瘤檢測市場（按應用）
  • 攝護腺
  • 胸部
  • 冒號
  • 子宮內膜
  • 肺
  • 惡性黑色素瘤
  • 其他
• 全球固態腫瘤檢測市場（依最終用途）
  • 醫院
  • 製藥和生物技術公司
  • 受託研究機構
  • 學術研究所

第4章。各地區市場趨勢及預測分析（2019-2031）

• 固態腫瘤檢測市場（按地區）
• 北美固態腫瘤檢測市場
• 歐洲固態腫瘤檢測市場
• 亞太固態腫瘤檢測市場
• 世界其他地區固態腫瘤檢測市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球固態腫瘤檢測市場成長機會（按類型）
  • 全球固態腫瘤檢測市場的成長機會（按應用）
  • 全球固態腫瘤檢測市場的成長機會（按最終用途分類）
  • 全球固態腫瘤檢測市場各區域成長機會
• 全球固態腫瘤檢測市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球固態腫瘤檢測市場的產能擴張
  • 全球固態腫瘤檢測市場的合併、收購和合資企業
  • 認證和許可

第7章主要企業簡介

• Agilent Technologies
• MYRIAD GENETICS
• Biocare Medical
• ILLUMINA
• F. Hoffmann-La Roche
• QIAGEN
• MedGenome Labs
• Thermo Fisher Scientific
• Abbott Laboratories
• QUEST DIAGNOSTICS

The future of the global solid tumor testing market looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1699.2 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are the increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.

• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
• In terms of regions, North America is expected to witness the largest growth over the forecast period due to a rise in various organ-specific cancer cases, supported by a robust healthcare infrastructure.

Gain Valuable Insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Solid Tumor Testing Market

The solid tumor testing market is being shaped by emerging trends in the field that are changing the aspects of diagnostics and treatment methods. These trends are marked by differences in technologies, changes in the healthcare system, and a shift in focus toward the patient.

• Liquid Biopsy Technology: Liquid biopsy technology includes the examination of liquid samples from patients to identify solid tumors by analyzing circulating tumor DNA (ctDNA). Monitoring tumor behavior and its changes can help improve the personalization of treatment and decrease the number of invasive procedures used.
• Genomic Profiling: Comprehensive genomic profiling is becoming an essential component of cancer management as it helps in the detection of mutations in different tumors. In this context, agents that promote the creation of drugs that target specific molecules are likely to be beneficial to patients, especially in cases of cancer types with metastatic potential.
• Integration of AI and Machine Learning: The use of AI and machine learning in performing solid tumor tests improves the accuracy and speed of diagnosis. Such technologies analyze vast amounts of data to identify potential trends and forecast the outcomes of treatments, assisting doctors in formulating appropriate treatment measures.
• Increased Focus on Early Detection: There is an increasing focus on the early detection of solid tumors, as this significantly increases the chances of successfully treating affected individuals. There is a need to develop strategies for providing regular check-ups and advanced diagnostic approaches to ensure that cancers are detected at an earlier stage when they are most treatable.
• Regulatory Attitude Towards Technology: Regulatory authorities have started to recognize and promote more innovative and novel diagnostic solutions, which accelerate the approval of new technologies and streamline the approval systems. This scenario is supportive of both the establishment and practice of research and development, which will, in turn, increase the chances of these sophisticated testing procedures becoming commonplace in routine use.

These new trends are revitalizing the solid tumor testing segment of the market by strengthening the capabilities of diagnostics, encouraging targeted approaches, and improving the healthcare provided. With the rapid rate of technological changes, it will not be surprising to find that all these trends will be integrated in further tackling the problems associated with cancer.

Recent Developments in the Solid Tumor Testing Market

The market for solid tumor testing has its share of developments that stand out with improvements in the accuracy and management of treatment. Such trends are all towards an increase in personalized medicine and a demand for advancements in treatment technology concerning cancer.

• Liquid Biopsy Advancements: Recent developments in the liquid biopsy field have allowed for the non-invasive detection of solid tumors via the analysis of ctDNA bioassays. This development significantly augments the surveillance of patients and any changes that may be made in the course of treatment, showing how the tumor is behaving as well as the effects of the treatment given.
• Genomic Profiling Approvals: The endorsement of policies for the approval of diverse molecular profiling tests by health regulators has made access to selected therapies easier. Using these tests, oncologists can isolate certain mutations that, in turn, lead to tailored surgical intervention plans that improve positive outcomes and reduce negative effects in patients.
• AI-Driven Diagnostics: The use of artificial intelligence systems in testing solid tumors is changing the way things are done in the industry. AI techniques are better equipped to evaluate multifaceted data compared to traditional approaches, thereby making diagnosis and treatment processes faster by providing more informed treatment options for patients.
• Collaborative Research Initiatives: Collaboration between universities and biotech firms has fostered the improvement of cancer diagnostic techniques. International collaboration, for example, supports technology development and improves testing strategies so that advanced technologies reach clinicians more quickly.
• Global Standardization Efforts: The global standardization movement of solid tumor biological diagnostic testing procedures is gaining the momentum it deserves. It seeks the harmonization of diagnostic testing strategies so that uniformity and reproducibility of particular tests are achieved, which will, in turn, improve the quality of care for patients worldwide.

These key advancements have benefited the solid tumor testing market through better diagnosis, extended treatment alternatives, and effective patient management. It is clear that emphasizing the challenges and possible solutions brings about more opportunities for future developments in this field.

Strategic Growth Opportunities for Solid Tumor Testing Market

The geometrical progression that attracts attention in the area of solid tumor testing encompasses diverse strategic exclusion options related to the component geosystems basis territory diversified. The development of specific potential values helps address the challenges that enhance the diagnosis processes and treatment outcomes.

• Introduction of Personalized Medicine: Personalized medicine has made it possible to design unique tests that are appropriate for an individual patient. A comprehensive investigation of genes can help devise new strategies that are more effective in treating diseases and improving the health status of patients.
• Advancing the Liquid Biopsy Market: Looking at the growing trend of non-invasive testing, companies have an opportunity to enhance their liquid biopsy systems and services. This trend helps not only to make patients comfortable but also allows better measurement of treatment response.
• Using AI Technology for Diagnostics: The application of AI in solid tumor testing creates new pathways for the development of intelligent diagnostic solutions. These can sift through a massive amount of information systematically to improve the accuracy of tests, increase workflow efficiency, and reduce the time taken to arrive at a diagnosis.
• There is a growing need for early detection: Increased understanding of cancer and its early symptoms has necessitated the need for better screening tools. Thus, companies that invest in bringing forth better early detection tests for the market can gain more from this growing need in the industry, which, in turn, leads to a larger market share from the expanding clientele.
• Developed Markets Target-Expansion of Overseas Operations: Emerging markets, especially in Asia and Africa, will prove to be great avenues for the solid tumor testing business. Companies that can strategically enter these areas will find an increasing number of patients seeking better ways to diagnose their diseases.

These forward-looking growth strategies are redefining the solid tumor testing market by focusing on precision medicine, technology, and novel diagnostic solutions. Providers who pursue these opportunities will capture more market share and enhance the quality of care provided to patients.

Solid Tumor Testing Market Driver and Challenges

Similar to solid tumor testing within the market, the upcoming solid tumor testing market also suffers from several technological, economic, and regulatory factors that act as both enablers and inhibitors. Understanding these dynamics is important for stakeholders as the environment continues to change.

The factors responsible for driving the solid tumor testing market include:

1. Technological Advancements: Technological innovations in testing methods, including liquid biopsies and genomic profiling, are fueling the market. Most importantly, these innovations increase accuracy, target specific therapies, and improve patient access to diverse treatments.

2. Increasing Cancer Incidence: The increasing global burden of cancer is demanding better testing techniques. As more people request early diagnosis services and suitable therapies, the market for solid tumor testing continues to grow.

3. Shift Towards Individualized Treatment: There is a paradigm shift in solid tumor testing driven by an increasing focus on precision medicine. More and more, patients and providers are looking for tests that can reveal particular mutations that can then be treated with more effective targeted therapies.

4. Government Policy Encouragement: Regulatory authorities are promoting innovative testing ideas and shortening the duration of introducing new devices to the market. This atmosphere favors conducting R&D activities, which ultimately results in an increased supply of modern and advanced diagnostic equipment.

5. Growth in Healthcare Financing: Growth in the solid tumor testing market is fueled by investment in healthcare infrastructure and biotechnology by public and private institutions. Improved funding facilitates the creation and use of sophisticated diagnostic approaches.

Challenges in the solid tumor testing market include:

1. Regulatory Hurdles: Although regulatory endorsement is acquired in some cases, it is not straightforward to gain approval for new technology. Innovative companies experience problems launching their cutting-edge solutions, which negatively impacts competition.

2. Market Fragmentation: The market for testing malignant secondary tumors is poorly consolidated, and many stakeholders offer different services. This fragmentation leads to confusion among medical practitioners and patients, resulting in poor choices regarding testing.

The balance of factors that support the development and barriers to the expansion of the solid tumor testing market is quite evident. It is essential to utilize available technological developments and address challenges to improve patient care and foster the effective and progressive development of cancer diagnostics.

List of Solid Tumor Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies solid tumor testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include-

• Agilent Technologies
• MYRIAD GENETICS
• Biocare Medical
• ILLUMINA
• F. Hoffmann-La Roche
• QIAGEN
• MedGenome Labs
• Thermo Fisher Scientific
• Abbott Laboratories
• QUEST DIAGNOSTICS

Solid Tumor Testing by Segment

The study includes a forecast for the global solid tumor testing market by type, application, end use, and region.

Solid Tumor Testing Market by Type [Analysis by Value from 2019 to 2031]:

• Genetic Testing
• Conventional Testing

Solid Tumor Testing Market by Application [Analysis by Value from 2019 to 2031]:

• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others

Solid Tumor Testing Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions

Solid Tumor Testing Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Solid Tumor Testing Market

The solid tumor testing market is undergoing dramatic changes in some countries primarily due to technological breakthroughs and increases in healthcare expenditure and focus on personalized medicine. This is particularly true for the United States, China, Germany, India, and Japan, each of which is progressing in specific areas to enhance diagnostic devices and therapeutic approaches.

• USA: There is rapid development of liquid biopsy technologies, which revolutionize the way cancer is diagnosed through non-invasive methods for solid tumors that do not require invasive surgery. With the increasing number of approvals for genomic profiling tests, it is possible to develop targeted therapies. Apart from this, partnerships between biotech companies and healthcare providers enhance diagnostics.
• China: Such development in China regarding the solid tumor market is observed primarily because of the influx of public funds in the field of biotechnology, including healthcare. An increase in inhibitory activity in management, including management of precision medicine programs, is witnessed with a growing volume in the utilization of complicated genomic tests. No affordable management has grown this change for focal management specifically at centers, as they reduce the rate of delay and assist in developing better management strategies.
• Germany: Germany's solid tumor testing market is supported by impressive research activity and collaboration between research institutes and businesses. The country is moving toward next-generation sequencing (NGS) technologies, which further improve diagnostic accuracy and support the implementation of specific treatments. Innovative testing approaches are also being accepted, as improvements in regulatory guidance encourage the development of new diagnostic methods.
• India: The solid tumor testing market is fueled by the growing incidence of cancer among the population in India. Low-cost genomic diagnostic tests, developed for the majority of the population by emerging companies, promote early diagnosis and treatment personalization. Improvements in cancer diagnostics are also aided by increased public awareness and government policies.
• Japan: Japan is expanding its solid tumor testing market by employing new imaging methodologies along with NGS in the field of solid tumors. The government is encouraging doctors to adopt precision medicine concepts, resulting in more mechanisms for treating cancers. Marketing drafts created in cooperation with Japanese companies and foreign companies have expanded the supply of new diagnostic methods.

Features of the Global Solid Tumor Testing Market

Market Size Estimates: Solid tumor testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Solid tumor testing market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Solid tumor testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, end use, and regions for the solid tumor testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Solid Tumor Testing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Solid Tumor Testing Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Solid Tumor Testing Market by Type
  • 3.3.1: Genetic Testing
  • 3.3.2: Conventional Testing
• 3.4: Global Solid Tumor Testing Market by Application
  • 3.4.1: Prostate
  • 3.4.2: Breast
  • 3.4.3: Colorectal
  • 3.4.4: Endometrial
  • 3.4.5: Lung
  • 3.4.6: Melanoma
  • 3.4.7: Others
• 3.5: Global Solid Tumor Testing Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Pharmaceutical & Biotechnology Companies
  • 3.5.3: Contract Research Organizations
  • 3.5.4: Academic Research Institutions

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Solid Tumor Testing Market by Region
• 4.2: North American Solid Tumor Testing Market
  • 4.2.1: North American Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.2.2: North American Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.3: European Solid Tumor Testing Market
  • 4.3.1: European Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.3.2: European Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.4: APAC Solid Tumor Testing Market
  • 4.4.1: APAC Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.4.2: APAC Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.5: ROW Solid Tumor Testing Market
  • 4.5.1: ROW Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.5.2: ROW Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Solid Tumor Testing Market by Type
  • 6.1.2: Growth Opportunities for the Global Solid Tumor Testing Market by Application
  • 6.1.3: Growth Opportunities for the Global Solid Tumor Testing Market by End Use
  • 6.1.4: Growth Opportunities for the Global Solid Tumor Testing Market by Region
• 6.2: Emerging Trends in the Global Solid Tumor Testing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Solid Tumor Testing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Solid Tumor Testing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Agilent Technologies
• 7.2: MYRIAD GENETICS
• 7.3: Biocare Medical
• 7.4: ILLUMINA
• 7.5: F. Hoffmann-La Roche
• 7.6: QIAGEN
• 7.7: MedGenome Labs
• 7.8: Thermo Fisher Scientific
• 7.9: Abbott Laboratories
• 7.10: QUEST DIAGNOSTICS